Maprotiline HCl Rx
Generic Name and Formulations:
Maprotiline HCl 25mg, 50mg, 75mg; tabs.
Indications for Maprotiline HCl:
Treatment of depressive illness in patients with depressive neurosis (dysthymic disorder) and manic-depressive illness, depressed type (major depressive disorder). Relief of anxiety associated with depression.
Mild-moderate depression: initially 75mg daily; maintain for 2 weeks, may increase in 25mg increments as required and tolerated. Usual max 150mg daily. Severely depressed or hospitalized: initially 100–150mg daily; may increase to max 225mg daily if necessary. Maintenance: use lowest effective dose; may be reduced to 75–150mg daily; adjust as needed. Elderly (>60yrs): initially 25mg daily; maintenance therapy: 50–75mg daily.
<18yrs: not recommended.
Seizure disorder. Within 14 days of MAOIs. Acute phase of MI.
History of MI. Cardiovascular disease. Discontinue prior to elective surgery. Increased intraocular pressure. Urinary retention. Narrow-angle glaucoma. Hyperthyroidism. Monitor leukocyte and differential counts in patients who develop fever and sore throat; discontinue if evidence of pathological neutrophil depression. Write ℞ for smallest amount needed. Pregnancy (Cat.B). Nursing mothers.
See Contraindications. Potentiates CNS depression with concomitant alcohol, barbiturates, other CNS depressants. Additive atropine-like effects with anticholinergics, sympathomimetics. Avoid concomitant electroshock therapy. Potential for cardiovascular toxicity with thyroid drugs. May antagonize guanethidine. Concomitant phenothiazines, or rapid tapering of benzodiazepines: increased risk of seizures. May be potentiated by hepatic enzyme inhibitors (eg, cimetidine, fluoxetine). May be antagonized by hepatic enzyme inducers (eg, barbiturates, phenytoin).
Drowsiness, dry mouth, nervousness, dizziness, constipation, blurred vision, tremor, GI upset, anxiety, insomnia, weakness, fatigue, headache, agitation.
Formerly known under the brand name Ludiomil.
Psychiatry Advisor Articles
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV
- Maintenance rTMS for Treatment-Resistant Depression
- New Study Compares Opioid Dependence Relapse Treatments
- Increase Use of Nursing Home for Patients With Cognitive Impairment Category
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder